Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) announced participation in the Cantor Fitzgerald Virtual Global Healthcare Conference 2021 on September 29, 2021, at 3:20 PM E.T. The event will be accessible via live webcast on the company's website and archived for 30 days post-presentation. Provention Bio focuses on developing therapies to intercept and prevent immune-mediated diseases such as type 1 diabetes and lupus. For more details, visit www.ProventionBio.com.

RED BANK, N.J., Sept. 23, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021 on Wednesday, September 29, 2021 at 3:20 pm E.T.

The fireside chat will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts:

Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235

Sam Martin, Argot Partners
proventionbio@argotpartners.com   
212-600-1902

Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-cantor-fitzgerald-virtual-global-healthcare-conference-2021-301383432.html

SOURCE Provention Bio, Inc.

FAQ

When is Provention Bio's presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021?

Provention Bio will present on September 29, 2021, at 3:20 PM E.T.

How can I watch Provention Bio's presentation at the conference?

The presentation will be available via live webcast on the company's website.

What is the focus of Provention Bio, Inc.?

Provention Bio focuses on developing therapies for immune-mediated diseases, including type 1 diabetes and lupus.

Where can I find more information about Provention Bio?

More information can be found on Provention Bio's website at www.ProventionBio.com.

Will the webcast of Provention Bio's presentation be available later?

Yes, the webcast will be archived on the company's website for 30 days following the presentation.